- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 65,18 | -1,12 % | Biogen posts mid-stage trial data for Alzheimer's candidate developed with Ionis | ||
| CSPC PHARMA | 0,863 | +1,86 % | CSPC PHARMA (01093): DATE OF BOARD MEETING | ||
| SELLAS LIFE SCIENCES | 6,160 | +0,65 % | SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses | ||
| ACADIA PHARMACEUTICALS | 18,910 | +0,37 % | Acadia Pharmaceuticals Inc.: Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome | Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed the company it has formally... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 458,20 | +1,60 % | Truist raises Madrigal Pharmaceuticals stock price target on MASH survey | ||
| CATALYST PHARMACEUTICALS | 26,800 | -0,37 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results | Delivered Q1 2026 Total Revenues of $149.4 MillionResults include 28% YoY Increase in Net Product Revenues from FIRDAPSE® & AGAMREE® Reported Cash and Cash Equivalents of $755.9 Million and No Funded... ► Artikel lesen | |
| OPUS GENETICS | 4,320 | +4,35 % | Opus Genetics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets | Northvale, New Jersey--(Newsfile Corp. - April 2, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,460 | +2,93 % | Savara Inc - 10-Q, Quarterly Report | ||
| GALECTIN THERAPEUTICS | 1,950 | +3,72 % | Galectin Therapeutics GAAP EPS of -$0.08 misses by $0.02 | ||
| BIODEXA PHARMACEUTICALS | 3,180 | -3,64 % | Biodexa Pharmaceuticals PLC: Biodexa issues letter to Shareholders | May 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or... ► Artikel lesen | |
| NEURIZON THERAPEUTICS | 0,038 | 0,00 % | Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 Study | ||
| CIPHER PHARMACEUTICALS | 10,500 | -9,48 % | Cipher Pharmaceuticals GAAP EPS of $0.24 beats by $0.10, revenue of $12.51M beats by $0.31M | ||
| ACURA PHARMACEUTICALS | - | - | ACURA PHARMACEUTICALS, INC - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB |
Das Unternehmen LOTUS PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.